Previous 10 | Next 10 |
home / stock / vph:cc / vph:cc news
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023 Canada NewsWire Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with pri...
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS Canada NewsWire MONTREAL , April 28, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceuti...
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE Canada NewsWire MONTREAL , April 19, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VP...
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company had a record quarter in the three months to January 31, 2023, with revenue of $13.2 million, up 210% over 1Q 2022. Saviuk tells Proactive this marks the 5th consecutive quarter of g...
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023 Canada NewsWire Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22 Fifth consecutive quarter of adjusted gross profit increase at $4.2 million ...
NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held on March 9th are now available for online viewing. REGISTER NOW AT : ...
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , March 9, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, annou...
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum to be held March 9 th . Individual investors, institutional investors, advisors, and analysts ...
MONTREAL, March 06, 2023 (GLOBE NEWSWIRE) -- Valeo Pharma Inc . (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Steve Saviuk, CEO, will present live at the Life Science Investor Forum, ho...
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has obtained public reimbursement from the Quebec Government for its product Onstryv (safinamide). Saviuk told Proactive Health Canada approved Onstryv as an add-on therapy for the ...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
--News Direct-- Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million ...
VALEO PHARMA REPORTS RECORD SECOND QUARTER 2024 REVENUES Canada NewsWire Record Q2-24 revenues of $14.1 million , up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million fo...